VICTORIA, Aug. 29, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), announces the Company is now an approved contract research organization ("CRO") for developing human monocolonal antibodies using the OmniAb® platform of transgenic mice and rats.
The OmniAb® platform consists of the OmniRat®, OmniMouse® and OmniFlic® transgenic rodents. These rodents are bred to produce highly diversified antibody repertoires for the discovery of fully human antibodies with potentially superior therapeutic efficacy and reduced immunogenicity. The OmniAb® platform is owned by Ligand Pharmaceuticals.
ImmunoPrecise Antibodies has now completed two research and development projects, which allowed the Company to test and optimize its unique and proprietary methodologies, including the Rapid Prime immunization protocol.
These two projects were conducted on behalf of Aptevo Therapeutics ("Aptevo") of Seattle, Washington and Tizona Therapeutics ("Tizona") of San Francisco, California. In these projects ImmunoPrecise leveraged the power of its internal antibody development process to develop human monoclonal antibodies for two different cell surface therapeutic targets.
"We are pleased with both the execution and outcome of this recent campaign which generated a large number of unique antibodies that will be evaluated in our ADAPTIRTM bispecific platform," said Dr. David Bienvenue, Senior Director, Protein Sciences of Aptevo Therapeutics.
"The combined approach gave us a diverse repertoire of antibodies to test in our assays. We were very pleased with the outcome of this development project," said Dr. Vanessa Soros, Senior Principal Scientist at Tizona Therapeutics.
ImmunoPrecise Antibodies Chief Scientific Officer Dr. Deanna Dryhurst, stated, "These research and development projects allowed us to qualify as an official CRO as well as validate that our methodologies performed exceptionally well. We see increasing demand and interest in human monoclonal antibody development."
About ImmunoPrecise Antibodies Ltd.
The Company provides custom antibody engineering and production services and protein expression to support research and development programs at leading pharmaceutical and biotechnology companies, as well as academic research laboratories.
Antibodies are naturally occurring proteins capable of binding to specific target molecules, or antigens. They have been used very widely in research assays, diagnostics, purification, biologics and therapeutics.
The Company operates from state of the art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia which house its tissue culture and molecular facilities as well as an animal care unit, and is a member of the Canadian Council for Animal Care.
The services offered to customers include the development of mouse and rat monoclonal and rabbit recombinant monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically based assays, and solutions to challenges faced by clients in antibody related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by the Company target a wide variety of environmental, diagnostic and research applications.
The Company employs a highly experienced group of R&D scientists. Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. ImmunoPrecise uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things: risks and uncertainties described in the Company's Filing Statement dated December 13, 2016 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
For further information: please contact: ImmunoPrecise Antibodies Ltd., Phone: 1-250-483-0803, 3204-4464 Markham Street, Victoria, BC V8Z 7X8, www.immunoprecise.com; For investor relations please contact: Rob Gamley, Phone: 1-604-689-7422, Email: [email protected], Contact Financial Corp., 1450 - 701 West Georgia St., Vancouver, BC V7Y 1G5